Sepsis Diagnostics Market Forecasts to 2028 – Global Analysis By Test Type (Laboratory Tests, Point-of-Care Tests and Other Test Types), By Pathogen (Bacterial Sepsis, Viral Sepsis, Fungal Sepsis and Other Pathogens), By Method, By Product, By Technology,

Sepsis Diagnostics Market Forecasts to 2028 – Global Analysis By Test Type (Laboratory Tests, Point-of-Care Tests and Other Test Types), By Pathogen (Bacterial Sepsis, Viral Sepsis, Fungal Sepsis and Other Pathogens), By Method, By Product, By Technology, By End User and By Geography

According to Stratistics MRC, the Global Sepsis Diagnostics Market is accounted for $686.7 million in 2022 and is expected to reach $1326.8 million by 2028 growing at a CAGR of 11.6% during the forecast period. When the immune system of the body assaults its own tissues in response to an infection, sepsis, a potentially lethal condition, develops. Organs perform badly and inappropriately when the body's infection-fighting mechanisms are activated. Sepsis can lead to septic shock. This unexpected drop in blood pressure can seriously harm organs and even result in death. The likelihood of survival is improved by receiving intravenous fluids and antibiotics as soon as feasible.

According to the Global Sepsis Alliance in April 2020, around 30% of COVID-19 patients had evidence of liver injury and around 75% reported a depressed immune response in Seattle, U.S.

Market Dynamics:

Driver:

Rising incidence of hospital-acquired infections

Nosocomial infections, sometimes referred to as hospital-acquired infections or HAIs, are a leading global cause of morbidity and mortality. Urinary tract infections, pneumonia, and sepsis are the most typical hospital acquired infections (HAIs). In immune compromised individuals, geriatric patients, and people with chronic conditions, HAIs can result in sepsis. In the coming years, there will be an increase in need for appropriate sepsis diagnostic devices due to the worldwide rapid increase in HAIs. As a result, it is anticipated that the market for sepsis diagnostics would rise as a result of the increasing prevalence of hospital-acquired illnesses.

Restraint:

High cost of automated diagnostic devices

When compared to blood culture tests, which can be purchased for as little as USD 28–35, the price of molecular diagnostic testing is between $300 and $3,000, which is extremely exorbitant. Due to tight finances, government hospitals (particularly in developing countries) and academic research labs are unable to purchase the automated diagnostic gadgets that companies are concentrating on developing for identifying sepsis. These devices are based on advanced technology, such as molecular diagnostics. Moreover, it is increasingly the main obstacle to market expansion.

Opportunity:

Evolution of novel biomarkers for sepsis diagnosis

Even with the present availability of extended-spectrum antibiotics and cutting-edge medical care, sepsis remains one of the major causes of mortality and morbidity. In order to facilitate early diagnosis, identify patient populations at high risk of complications, and track the course of the disease, which are vital measures for effective therapy and bettering patient outcomes, biomarkers offer a tool. Additionally, the introduction of efficient treatments and ongoing clinical trials will create favourable chances for the sepsis diagnostics market during the anticipated time frame.

Threat:

Shortage of skilled healthcare professionals

Sepsis is a potentially fatal condition that requires prompt diagnosis and treatment from trained medical personnel. Only 50% of patients with severe sepsis conveyed by the EMS system had a paramedic, which raises serious concerns about the global talent deficit. Each stage of patient treatment is impacted by a shortage of qualified paramedics, including sepsis awareness, sepsis screening, and making an accurate diagnosis.

Covid-19 Impact

Diagnostics for sepsis sales increased as a result of the COVID-19 epidemic. Sepsis detection tools, reagents, and test kits are expected to be more quickly adopted as a result of the COVID-19 pandemic's rapid global spread and the rise of sepsis cases among COVID-19 patients. As older people are more susceptible to complications like acute respiratory distress syndrome (ARDS), which is typically brought on by pneumonia and increases the risk of sepsis, the current worldwide crisis has drawn attention to the hazards that older people confront. The need for early sepsis diagnosis in patients with COVID-19 infections is therefore increased.

The molecular diagnostics segment is expected to be the largest during the forecast period

The molecular diagnostics segment is estimated to have a lucrative growth, due to the adoption of molecular diagnostic technology because of its many benefits, including high sensitivity, accuracy, and quick turnaround times compared to other technologies. This technique's drawback is that it is unable to detect organisms that are impossible to cultivate. Nevertheless, following blood culture, the molecular diagnostics method is regarded as a standard method for identifying pathogens. The more sensitive, specific, and expedient nature of molecular diagnostic solutions is anticipated to drive the segment's expansion over the course of the forecast period.

The laboratory tests segment is expected to have the highest CAGR during the forecast period

The laboratory tests segment is anticipated to witness the highest CAGR growth during the forecast period, due to the fact that when identifying sepsis, lab testing is more accurate than POC testing. Hospital acquired infections (HAIs) are on the rise among hospitalised patients, and healthcare infrastructure improvements, particularly in developing nations, are expected to help the laboratory testing market grow. The segment is expanding in part due to the fact that most diagnoses are made in labs.

Region with largest share:

North America is projected to hold the largest market share during the forecast period, attributed to the region's increased use of modern diagnostic technologies as a result of the presence of an established healthcare infrastructure. Additionally, the market expansion in this area is being fuelled by the substantial presence of important competitors and a favourable reimbursement system. Moreover, it is anticipated that the rising prevalence of infectious illnesses and sepsis will increase need for cutting-edge diagnostic methods.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. It is projected that the rapid technological advancements and rising public awareness will drive market expansion. Additionally, there is an increasing demand for Sepsis diagnostic tools in countries with a high frequency of infectious diseases. A rise in regional and worldwide players' efforts to permit coverage of cutting-edge scientific robotic technology is another factor contributing to this region's profitable expansion.

Key players in the market

Some of the key players profiled in the Sepsis Diagnostics Market include Abbott Laboratories Inc., Amara Health Analytics, Beckman Coulter, Inc, Becton, Dickinson and Company (BD), Bruker Corporation, Cerner Corporation, Cube Dx GmbH, Danaher Corporation, EKF Diagnostics, Epic Systems Corporation, GE Healthcare, Koninklijke Philips N.V., Luminex Corporation, McKesson Corporation, Response Biomedical Corp., T2 Biosystems Inc. and Thermo Fisher Scientific, Inc.

Key Developments:

In December 2021, Immunoexpress received the United States Food and Drug Administration (FDA) approval for SeptiCyte RAPID.

In October 2021, Prenosis Inc., a precision diagnostics firm that uses artificial intelligence to enhance clinical diagnosis, expanded its existing agreement with Roche Diagnostics to improve and speed the clinical detection of sepsis.

In May 2020, Beckman Coulter announced the availability of its DxH 690T hematology analyzer in the U.S. which is used as the early sepsis indicator. This announcement has helped company to increase its global presence and growth in the revenue as well.

Test Types Covered:
• Laboratory Tests
• Point-of-Care Tests
• Other Test Types

Pathogens Covered:
• Bacterial Sepsis
• Viral Sepsis
• Fungal Sepsis
• Other Pathogens

Methods Covered:
• Conventional Diagnostics
• Automated Diagnostics
• Other Methods

Products Covered:
• Software
• Instruments
• Assays & Reagents
• Blood Culture Media
• Other Products

Technologies Covered:
• Biomarkers
• Microfluidics
• Flow Cytometry
• Molecular Diagnostics
• Immunoassays
• Microbiology
• DNA Microarrays
• Syndromic Panel testing
• Other Technologies

End Users Covered:
• Research Laboratories & Academic Institutes
• Pathology & Reference Laboratories
• Hospitals and Specialty Clinics
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements